Company intelligence / Profile preview

ACEA Therapeutics

San Diego, California, United Statesacea.auto ↗

Ownership: Private
Development stage: Other

Overview

ACEA has completed a pivotal Phase III trial for Olgotrelvir in COVID‑19 (>1200 patients). Abivertinib has shown positive results in Phase II for EGFR T790M+ NSCLC and received FDA IND clearance for further studies. Multiple small molecule kinase inhibitors and large molecule/cell therapies are at various clinical stages targeting cancer and autoimmune diseases.

Therapeutic areas: OncologyImmunologyHematologyNeurologyInfectious Diseases
Modalities: Small moleculeAntibody-drug conjugateGene therapyCell therapy
Industry: Biotech

Partnerships

Lilly Asia VenturesQiming Venture Partners

Beyond the preview

Go deeper on ACEA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACEA Therapeutics.

Explore the full profile